Craniosynostosis, a condition where skull sutures fuse prematurely in children, can raise concerns about intracranial hypertension (ICH) – increased pressure within the skull. Traditionally, diagnosing ICH relies on invasive procedures. This review examines a promising new approach: handheld optical coherence tomography (OCT). Analyzing studies on handheld OCT use in children with craniosynostosis, we explore its feasibility, advantages, and potential role in improving diagnosis and patient care.
Craniosynostosis affects 1 in 2,000 newborns, often requiring surgery to correct skull shape and prevent complications. A significant concern is intracranial hypertension (ICH), which can damage the brain and vision if left untreated. Traditionally, diagnosing ICH involves invasive procedures like lumbar punctures or intracranial pressure monitoring. These methods are not ideal for young children, prompting the search for non-invasive alternatives.
Optical coherence tomography (OCT) is a revolutionary imaging technique that uses light to create detailed cross-sectional images of tissues. Recent advancements have led to the development of handheld OCT devices, making them more portable and user-friendly for pediatric applications. This review focuses on the feasibility of handheld OCT in diagnosing ICH in children with craniosynostosis.
Several studies have explored the use of handheld OCT in this context. These studies demonstrate promising results:
High Success Rates: Studies report successful image acquisition in a high percentage of children, exceeding 80% in some cases.
Feasibility for Young Children: Handheld OCT appears well-suited for young children, with good compliance and minimal discomfort.
Repeatability: Studies suggest good repeatability of OCT measurements, allowing for monitoring of pressure changes over time.
Handheld OCT offers several advantages over traditional methods for diagnosing ICH in children with craniosynostosis:
Non-invasive: Eliminates the need for needles or sedation, reducing risks and discomfort for children.
Quick and painless: OCT scans are completed in seconds, minimizing stress for patients.
Portable: Handheld devices allow for examinations at the bedside, improving accessibility.
Objective data: OCT provides quantitative measurements, aiding in diagnosis and monitoring.
While these initial studies are encouraging, further research is needed to fully establish handheld OCT as a standard diagnostic tool for ICH in children with craniosynostosis. Larger, multicenter trials are crucial to confirm its effectiveness and identify potential limitations. Additionally, exploring the correlation between OCT findings and other measures of ICH is important.
Handheld OCT holds immense potential for revolutionizing the diagnosis of ICH in children with craniosynostosis. This review highlights the feasibility, advantages, and future directions for this promising non-invasive technology. As research progresses, handheld OCT may become a valuable tool in improving early detection and management of ICH, leading to better outcomes for young patients.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
1.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation